Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02422979

Study Title
Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer (NCT02422979)

Trial Description
This is a Phase I, two part, study of patients with recurrent Head and Neck Cancer (HNC), who in the opinion of their physician, cannot be satisfactorily treated with surgery, radiation or platinum chemotherapy.

Part I is a drug dose-escalation, fixed low fluency light application study to determine the drug dose that can be safely given to saturate the epidermal growth factor receptor (EGFR) at the tumor.

Part II is a light dose-escalation, fixed drug dosing infusion study to determine the optimal light application, in combination with the Part I drug dose, needed to achieve clinical response with an acceptable safety profile. Interim analysis will be performed after completion of Part I and prior to initiation of Part II. This trial is sponsored by Aspyrian Therapeutics. [1]

Study Data

  • Condition: Head and Neck Cancer
  • Interventions:
    • Drugs used in this trial
      • RM-1929
      • Device: Photoimmunotherapy
  • Phase: I
  • Estimated Enrollment: 24
  • Start: June 2015
  • Estimated Completion: September 2016
  • Last verified: June 2015

Study Schematic 

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 8, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar